Retatrutide, a novel dual activator of the GLP-1 target and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising outcomes in early clinical trials . Ongoing research suggests https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/